Tag Archives: Triple Negative Breast Cancer

What is Triple Negative Breast Cancer


Triple negative breast cancer is a basal like breast cancer. I know that there are at least six types because it was stated at the San Antonio Breast Cancer conference that I attended in December.

Who gets triple negative breast cancer? Susan G. Komen states that 15-20 percent of all breast cancer in the United States are triple negative or basal like. Anyone can get it. Often though it occurs with younger women, African American women, Hispanic/Latina women, and women with a BRCA 1 mutation.

Today I got an e-mail from another women with Triple Negative breast cancer.

This cancer is harder to treat because it is limited. It lacks hormone receptors and hormone inhibitors cannot be used. Herceptin is not used because the tumor is often HER2/neu-negative.

If caught early it can be treated and chemo is used. In fact, chemo works better on this type of cancer than others. There are clinical trials going on all the time. Many of us wish there was more research being done in this area.

Triple negative breast cancer does not have bio-markers.

Triple Negative Breast Cancer is referred to as estrogen receptor-negative (ER-), progesterone receptor negative (PR-) and HER2/neu-negative.

This is a very aggressive type of tumor. It tends to grow fast and is not seen on a mammogram which could be once a year or every other year. It seems to come back compared to other types of breast cancer. I had a friend die of it.

Other Resources include:

Susan G. Komen or

Triple Negative Breast Cancer Foundation or

National Cancer Institute or

Living Beyond Breast Cancer or


Source of Information: Susan G. Komen





Triple Negative Breast Cancer

Triple Negative Breast Cancer

There are a couple of kinds of triple negative breast cancer. Some is thought to be genetic related to the BRCA 1/2 genes. In any event, young women, whether Caucasian or African American have a difficult time with it. Women who are older seem to have a more tolerable time.

First off, there are 182 oncogenes and tumor suppressors known to be present in human cancers. Triple negative breast cancer is driven by a diverse group of genetic alterations further down in some rabbit hole.  Not really, but it seems that way.

They found that an amplification of the anti-apoptosis gene MCL 1 occurs in 56% of the TNBC (Triple negative breast cancer).

They found that 33% had MYC amplification.

Then they found that the novel JAK2 gene, associated with cell proliferation, was found to be amplified in about 10% of patients and associated with poor survival.  They are looking at the JAK in inflammatory breast cancer.

HDAC or histone deacetylase, cystostatic agents may be used as targeted therapies in the future for Triple Negative Disease.

In the future they may be use PARP inhibitors, PARP inhibitors with HDAC and cisplatin for triple negative breast cancer.

Those patients who do not have a BRCA1 mutation should consider a clinical trial using a HDAC inhibitor in combination with a PARP inhibitor and cisplatin.


Posted by on December 15, 2012 in Business Health, Family Health, Mens Health, Womens Health

Comments Off


Triple Negative Breast Cancer, Male Breast Cancer, Ovarian Cancer

Triple Negative Breast Cancer

Did you know that TNBC accounts for approximately 15% of all breast cancers? 

60-90% of the tumors in BRCA 1 carries are triple negative.

In a recent study, 18% of unselected patients with triple negative breast cancer had BRCA1/2 mutations.

NCCN Testing criteria includes HBOC syndrome testing for patients with TNBC under age 60.

Source of Information: Myriad Genetics, Inc.

Male Breast Cancer

Multiple professional society guidelines state that a personal or family history of male breast cancer is a criterion for HBOC testing.

1 in 7 Ashkenazi Jewish males diagnosed with breast cancer will have a BRCA mutation. 1 in 14 non-Ashkenazi Jewish males diagnosed with breast cancer will have a BRCA mutation.

Men with BRCA mutations are at increased risk for several types of cancer. These include breast cancer, prostate cancer, pancreatic cancer, and melanoma.

Ovarian Cancer:

Multiple professional society guidelines state that a personal or family history of epithelial ovarian cancer is a criterion for HBOC testing.

55% of ovarian cancer patients at a major US cancer center were not aware of hereditary cancer testing.

89% of patients were willing to be tested if it would affect their therapy and 87% would be tested to benefit their family.

Source: Myraid Lab


Most insurance companies cover testing for patients with a history of the cancer listed. It is important to find out your personal and family history forms to see if you qualify for testing.


Tags: , , , ,